Welcome!

We are an emerging specialty biopharmaceutical company focused on the discovery, development, and commercialization of products for the topical treatment of inflammatory and infectious diseases. To date, our drug discovery and development efforts have generated a robust product pipeline, including one New Drug Application {"NDA") and two others in Phase II clinical trials. We have another product in late pre-clinical development targeting actinic keratosis and have formulated numerous product candidates targeting digital ulcers, plaque psoriasis, "age-spots", excessive hair growth and skin infections utilizing our proprietary topical drug delivery technology.

Each of our clinical drug candidates is based on our proprietary Topical AmphiMatrix ("TAM™") drug delivery technology. TAM is a versatile drug formulation that enables a range of therapeutic agents to be delivered locally through normal or thickened skin and nail. Our TAM technology has unique characteristics that enable it to more effectively deliver a variety of proven active agents to and through affected skin or nail while minimizing local irritation and systemic side effects as compared to other topical delivery technologies. It is applicable to a broad variety of therapeutic categories including peripheral vascular disorders, opportunistic infections, cutaneous and subcutaneous inflammatory diseases.